Find Clinical Trial
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Solid tumors |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
S049076 |
| Active Substance Code | S049076 |
| Protocol Code | CL1-49076-002 |
| EudraCT Code | 2013-003079-37 |
| ISRCTN Code | ISRCTN11619481 |
Documents and links
| Lay summary | |
| Results summary | READ MORE  |
Quote
| "Hoang-Xuan K and al. J Clin Oncol. 2016: 34(suppl) : 2033 (ASCO 2016)" |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
